Francesca Becherucci

E ora viaggi, ridi, vivi o sei perduta.

[Francesca Becherucci @FrancescaBeche]

Resistere è il più grande spettacolo dopo il Big Bang. A lezione da @esterviola

[Francesca Becherucci @FrancescaBeche]

@giammylugli Congratulations!

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

Early identification of CKD in pts with a solitary functioning kidney

🧐There is a need for long-term follow-up protocols in congenital single kidney pts from pediatric to adult nephrology care

▶️https://t.co/wHVv5cR1oZ

[Francesca Becherucci @FrancescaBeche]

Our new paper on #CKD in #solitarykidney is out in @NDTsocial. SFK is not a benign condition— patients require longlife follow up starting from childhood
Special thanks to @cirluigi

https://t.co/4SJpJgIYJu

[Francesca Becherucci @FrancescaBeche]

Thinking about a genetic disease is often a good idea, even in adults. Ordering genetic testing is essential, but make sure to consult a center with adequate expertise.

[ASN Publications @asnpublications]

Clinical and pathological confirmation of the diagnosis for CKD has limitations, with up to 1/3 of individuals remaining without a formal diagnosis. This study shows that genetic testing is informative in a high proportion of clinically selected adults.
https://t.co/LaIg1o0ae1

[Valentina Raglianti @RagliantiV]

Proud to share our paper in @Kidney_Int! Excited to see our research on anti-slit antibodies in steroid-resistant nephrotic syndrome published—a significant step toward targeted treatments. Huge thanks to my mentor @PRomagnani and @AngelottiLucia.
https://t.co/yNg5ad9Rui

[Hans-Joachim Anders @hjanders_hans]

Happy to see this finally out. The first study able to define the sensitivity and specificity of commercial anti-nephrin Ab by using kidney biopsies as gold standard. Standard Elisas do the job well. https://t.co/znMjDvR2g1

[Paola Romagnani @PRomagnani]

Look how much more important is to know if a patient is genetic or has anti-slit antibodies than if has MCD or FSGS at kidney biopsy.
We have finally come to the era of autoimmune, genetic and adaptive podocytopathies. No more MCD or FSGS used as diagnosis!

[Paola Romagnani @PRomagnani]

Anti-slit antibodies define response to therapy and prognosis much better than histopathological lesion patterns even among patients with steroid-resistant nephrotic syndrome https://t.co/S8duyCNcL9

[Francesca Becherucci @FrancescaBeche]

Thrilled to share our latest in @Kidney_Int Identifying anti-slit diaphragm antibodies is a game changer for patients with steroid-resistant nephrotic syndrome. Together with genetics, we can finally tailor treatments and improve outcomes.

https://t.co/7x1ZqVqnoT

[Francesca Becherucci @FrancescaBeche]

Our last review on kidney cancer in @NDTsocial
@cirluigi @SamanthaInnoce7

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

Global epidemiology of kidney cancer
@FrancescaBeche @cirluigi

https://t.co/APZgTw3pT8

[OMaR Malattie Rare @OssMalattieRare]

#NIPTtest (test DNA fetale), gratuito in Valle d’Aosta per le donne in gravidanza.

Considerato un valido mezzo di screening, non è stato inserito nei LEA che entreranno in vigore dal 1 aprile 2024. In tutte le altre regioni è a carico delle famiglie.
https://t.co/h7jfdFUaiJ

[Francesca Becherucci @FrancescaBeche]

La medicina sta andando da un’altra parte, ignorarlo è criminale

[OMaR Malattie Rare @OssMalattieRare]

L’onere dei costi per le famiglie con #malattierare sarà altissimo.

Dal 1° gennaio 2024 entrerà in vigore un nuovo nomenclatore che escluderà molte analisi genetiche.

📢 L'appello della @SIGU_97.

https://t.co/vTw5BJza50

[Francesca Becherucci @FrancescaBeche]

@DrFlashHeart Well done! I have a 4-months old baby and I gave up coming to Philly because I was afraid not to be able to manage

[Francesca Becherucci @FrancescaBeche]

Our editorial on #exome first strategies in medicine is out in @NDTsocial
Time to change perspective
@cirluigi @fondazionemeyer @UNI_FIRENZE

[Hans-Joachim Anders @hjanders_hans]

Now free online in @NDTsocial
Evolving role of first-tier exome sequencing in medical diagnostics https://t.co/IB5BehlFUK

[Francesca Becherucci @FrancescaBeche]

@AKronbichler Thank you!

[Francesca Becherucci @FrancescaBeche]

Finally out! Proud to be part of the PREDICT team!

[NEJM @NEJM]

In a trial involving infants with grade III, IV, or V vesicoureteral reflux and no previous UTI, continuous antibiotic prophylaxis for 2 years provided a small but significant benefit in preventing a first UTI. Full results of the PREDICT trial: https://t.co/YjosHHfqgf

[NEJM @NEJM]

With CRISPR-Cas9, a repressor of fetal hemoglobin expression was disrupted in hematopoietic stem cells from three persons with sickle cell disease. Edited cells were reinfused. Hematopoiesis was restored. Read the full study results: https://t.co/wa3S5ZdpsA

[Francesca Becherucci @FrancescaBeche]

Interesting paper. May the key be the clinical interpretation of results instead of the type of test?

[Genetics in Medicine @GIMJournal]

How can labs reduce the number of VUS reported in genetic testing? Exome and genome sequencing have lower VUS numbers compared to multi-gene panel tests. @HeidiRehm https://t.co/TukljYJaIn

[Muin J. Khoury @MuinJKhoury]

Why we need a genomics-savvy healthcare (and public health) workforce. Via @NatureMedicine https://t.co/9phWGt08it

[Francesca Becherucci @FrancescaBeche]

@elonmusk Good news for our hospitals @fondazionemeyer